In breast cancer, PRMT5 promotes tumor growth by methylating key substrates: it stabilizes KLF4 by inhibiting its ubiquitylation, leading to Bax downregulation and oncogene upregulation, and it methylates PDCD4, abolishing its tumor-suppressive function [296, 297]. Here, PDCD4 is linked to neoplasm.